ScholarIQanswers from OpenAlex & ORCID
Suresh S. Ramalingam
ResearcherPublications, citations & collaboration network
Suresh S. Ramalingam is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Suresh S. Ramalingam have?
ScholarIQindexed works
Suresh S. Ramalingam has 1,232 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Suresh S. Ramalingam have?
ScholarIQcitation count
Suresh S. Ramalingam has 99,629 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Suresh S. Ramalingam?
ScholarIQh-index
Suresh S. Ramalingam has an h-index of 125 in OpenAlex.
What is the i10-index of Suresh S. Ramalingam?
ScholarIQi10-index
Suresh S. Ramalingam has an i10-index of 480 in OpenAlex.
What is the ORCID of Suresh S. Ramalingam?
ScholarIQorcid
The ORCID for Suresh S. Ramalingam is on the source record.
What is the OpenAlex record for Suresh S. Ramalingam?
ScholarIQopenalex
The OpenAlex for Suresh S. Ramalingam is on the source record.
What are the most-cited papers on Suresh S. Ramalingam?
ScholarIQmost cited works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam